U.S. market Open. Closes in 6 hours

QNCX | Quince Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
RevenueN/AN/AN/AN/AN/AN/AN/A
Cost of Revenue322.00K175.00K344.00K332.00K188.00KN/AN/A
Gross Profit-322.00K-175.00K-344.00K-332.00K-188.00KN/AN/A
Operating Expenses34.62M51.19M90.32M78.89M39.17M12.12M10.37M
Selling, General & Admin15.39M26.01M29.52M17.59M8.95M2.03M1.27M
Research & Development9.45M25.18M60.80M61.31M30.21M10.09M9.10M
Other Operating Expenses9.78M-997.00K-247.00KN/AN/AN/AN/A
Operating Income-34.62M-52.02M-90.32M-78.89M-39.17M-12.12M-10.37M
Other Expenses / Income3.04M71.00K373.00K2.04M2.19M-206.00K-1.86M
Before Tax Income-31.58M-51.94M-89.94M-76.85M-36.98M-12.48M-12.23M
Income Tax Expenses197.00K-284.00K-620.00K2.17M-188.00K357.00KN/A
Net Income-31.39M-51.66M-89.33M-76.85M-36.79M-12.48M-12.23M
Interest ExpensesN/A568.00KN/AN/AN/A957.00K1.64M
Basic Shares Outstanding37.24M33.50M29.72M29.18M19.03M21.55M21.55M
Diluted Shares Outstanding37.24M33.50M29.72M29.18M19.03M21.55M21.55M
EBITDA-24.32M-50.16M-89.97M-76.52M-36.98M-11.26M-10.55M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-31.19M-51.38M-89.94M-74.68M-36.98M-11.16M-10.59M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙